Haleon’s EMEA Head Filippo Lanzi: There’s More To Innovation Than Rx-To-OTC Switch
Health literacy and natural alternatives are two areas where Haleon's EMEA and LATAM head Filippo Lanzi sees potential for growth, in addition to Rx-to-OTC switch, he tells HBW Insight in an exclusive interview. Lanzi also digs deeper into Haleon's recently published first-half sales and earnings results and shares his thoughts on how the firm will meet the multiple challenges posed by the current social and economic environment.
You may also be interested in...
Proposal for simultaneous Rx and OTC sales of same drug at same dose and indication has CHPA hoping FDA acknowledges Pataday and Voltaren Arthritis Relief are competing with Rx equivalents even though elimination of prescription NDAs was part of approvals for the two switches.
A better than expected first-half performance has put Haleon on a sure footing for the rest of the year following its recent demerger from GSK.
As GSK prepares to launch its standalone consumer health business, Haleon, Tess Player, global head of expert and influencer marketing, talks to HBW Insight about the new company's plans to improve health inclusivity globally and empower 50 million consumers per year to self-care by 2025.